S100A9 — Drug Target
All drugs that target S100A9 — marketed and clinical-stage. Includes 1 drug classes acting on this target.
Drug classes
Phase 2 pipeline (1)
- ABR-215050, tasquinimod · Active Biotech AB · Immunomodulator · Oncology
Tasquinimod is a quinoline-3-carboxamide derivative that modulates the immune system by targeting the S100A9 protein.